The increasing incidence of aciclovir- (ACV) resistant strains in patients with ocular herpes simplex virus (HSV) infections is a major health problem in industrialized countries. In the present study, the humanized monoclonal antibody (mAb) hu2c targeting the HSV-1/2 glycoprotein B was examined for its efficacy towards ACV-resistant infections of the eye in the mouse model of acute retinal necrosis (ARN). BALB/c mice were infected by microinjection of an ACV-resistant clinical isolate into the anterior eye chamber to induce ARN and systemically treated with mAb hu2c at 24 h prior (pre-exposure prophylaxis) or at 24, 40, and 56 h after infection (post-exposure immunotherapy). Mock treated controls and ACV-treated mice showed pronounced retinal damage. Mice treated with mAb hu2c were almost completely protected from developing ARN. In conclusion, mAb hu2c may become a reliable therapeutic option for drug/ACV-resistant ocular HSV infections in humans in order to prevent blindness.

, , , ,,
Department of Virology

Bauer, D. (Dirk), Keller, J. (Jessica), Alt, M. (Mira), Schubert, A. (Axel), Aufderhorst, U.W. (Ulrich Wilhelm), Palapys, V. (Vivien), … Krawczyk, A. (Adalbert). (2017). Antibody-based immunotherapy of aciclovir resistant ocular herpes simplex virus infections. Virology, 512, 194–200. doi:10.1016/j.virol.2017.09.021